NexImmune, Inc. (NEXI)
| Market Cap | 388.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 12.63M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $17.21 |
| Previous Close | $17.83 |
| Change ($) | -0.62 |
| Change (%) | -3.48% |
| Day's Open | 17.75 |
| Day's Range | 17.18 - 17.80 |
| Day's Volume | 24,790 |
| 52-Week Range | 17.06 - 28.00 |
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...
GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...
GAITHERSBURG, Md., May 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...
GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.
GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.
GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own...
NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy...
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.
NexImmune, Inc. has filed to go public with an IPO on the NASDAQ.
About NEXI
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, we have two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. It is important to note that we are earl... [Read more...]
| Industry Biotechnology | IPO Date Feb 12, 2021 |
| CEO Scott Carmer | Employees 44 |
| Stock Exchange NASDAQ | Ticker Symbol NEXI |
Analyst Forecasts
The average 12-month stock price forecast for NexImmune is 33.33, which is an increase of 93.67% from the latest price.